In addition, the long-term effects and side effects of GLP-1R agonists need more in-depth studies
These medications are administered subcutaneously, meaning they are injected into the fatty tissue layer beneath the skin rather than into muscle
Food and Drug Administration (FDA) has approved four GLP-1 drugs for weight loss in people with overweight or obesity: liraglutide (Saxenda) orforglipron (Foundayo) semaglutide (Wegovy) tirzepatide (Zepound) Liraglutide, semaglutide, and tirzepatide are injectable medications that come in prefilled pens
Clinical Evidence on GLP-1 Efficacy Across Approved Formulations Injectable GLP-1 receptor agonists demonstrate consistent weight reduction of 1522% body weight over 68 weeks in clinical trials, depending on dose and patient baseline metabolic factors
First, it slows digestion complementing the medication's own gastric-slowing effect to keep you fuller, longer
This is one reason sports medicine clinicians pay close attention to concepts like Relative Energy Deficiency in Sport (RED-S)
